FT 1050

Drug Profile

FT 1050

Alternative Names: 16, 16 dimethyl-prostaglandin E2; dmPGE2; FT1050; ProHema; ProHema-CB; Prostaglandin E2 - Fate Therapeutics

Latest Information Update: 22 Jun 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Childrens Hospital Boston; Massachusetts General Hospital
  • Developer Fate Therapeutics
  • Class Antineoplastics; Chemoprotectants; Prostaglandins; Small molecules
  • Mechanism of Action Stem cell modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Stem cell mobilisation
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Stem cell mobilisation

Most Recent Events

  • 11 Apr 2016 Fate Therapeutics terminates a phase-I trial in Stem cell mobilisation (In infants, In children, In adolescents with haematological malignancies) in USA (IV) (NCT02354417)
  • 11 Apr 2016 Fate Therapeutics terminates a phase I trial for Stem cell mobilisation (in paediatric patients with metabolic disorders) in USA (NCT02354443)
  • 03 Mar 2016 Discontinued - Phase-I for Stem cell mobilisation (In adolescents, In children, In infants) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top